Gilead Sciences, Inc. et al v. Natco Pharma Limited

1:22-cv-00852 | Delaware District Court

Interested in this case?

Request a Demo Track this case, and find millions of cases like it, let us show you how.
Division Wilmington
Judge Judge Richard G. Andrews
Filed June 23, 2022
Terminated Aug. 22, 2023
Case Flags CLOSED and PATENT
Nature of Suit 835 Patent - Abbreviated New Drug Application (ANDA)
Cause 35:271 Patent Infringement
Jury Demand None
Last Updated: 1 year, 1 month ago Show Interactive Timeline
Upcoming Events
4 Months
  • 7/21/2025
Date of Expiration of RE44,599 Patent: July 21, 2025.
Source
Add
4 Months
  • 8/5/2025
Date of Expiration of RE44,638 Patent: August 5, 2025.
Source
Add
Filing Date # Docket Text
8/22/2023Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE44,599 E; RE44,638 E; 8,865,730 B2; 9,469,643 B2; 10,730,879 B2. (Attachments: # 1 Consent Judgment)(nms) (Entered: 08/22/2023)
8/22/2023CONSENT Judgment and Dismissal Order. Signed by Judge Richard G. Andrews on 8/22/2023. Associated Cases: 1:22-cv-00852-RGA, 1:22-cv-01259-RGA(nms) (Entered: 08/22/2023)
8/21/2023 PROPOSED Consent Judgment and Dismissal Order, by Gilead Sciences, Inc., Gilead Calistoga, LLC. (Tigan, Jeremy) Modified on 8/22/2023 (nms). (Entered: 08/21/2023)
8/14/202342
  • Motion to ContinueGranted
ORAL ORDER: The request to continue the stay for an additional 14 days (D.I. 40 ) is GRANTED. Ordered by Judge Richard G. Andrews on 8/14/2023. (lah) (Entered: 08/14/2023)
8/14/2023REDACTED VERSION of 40 Status Report by Gilead Calistoga, LLC, Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 08/14/2023)
8/14/2023[SEALED] Joint STATUS REPORT by Gilead Calistoga, LLC, Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 08/14/2023)
6/30/202339
  • Motion to ContinueGranted
ORAL ORDER: The request to continue the stay for an additional 45 days (D.I. 37 ) is GRANTED. Ordered by Judge Richard G. Andrews on 6/30/2023. (nms) (Entered: 06/30/2023)
6/30/2023REDACTED VERSION of 37 Status Report by Gilead Calistoga, LLC, Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 06/30/2023)
6/30/2023[SEALED] Joint Status Report, by Gilead Calistoga, LLC, Gilead Sciences, Inc.. (Tigan, Jeremy) Modified on 6/30/2023 (nms). (Entered: 06/30/2023)
6/2/202336
  • Order
ORAL ORDER: The request for an additional 30 days to submit a joint status report (D.I. 34 ) is GRANTED. Ordered by Judge Richard G. Andrews on 6/2/2023. (nms) (Entered: 06/02/2023)
6/2/2023REDACTED VERSION of 34 Status Report by Gilead Calistoga, LLC, Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 06/02/2023)
6/2/2023[SEALED] Joint STATUS REPORT by Gilead Calistoga, LLC, Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 06/02/2023)
4/12/2023REDACTED VERSION of 31 Stipulation by Gilead Calistoga, LLC, Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 04/12/2023)
4/12/2023
  • Motion to Stay ProceedingsGranted
[SEALED] ORDER Granting 31 Stipulation and Proposed Order to Stay Proceedings. Signed by Judge Richard G. Andrews on 4/12/2023.This order has been emailed to local counsel. (nms) (Entered: 04/12/2023)
4/12/2023
  • Motion to Stay Proceedingsby Π
[SEALED] STIPULATION and [Proposed] Order to Stay Proceedings by Gilead Calistoga, LLC, Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 04/12/2023)
4/11/2023SO ORDERED Granting 29 Stipulation of Dismissal of Eli Lilly and Company and ICOS Corporation. Signed by Judge Richard G. Andrews on 4/11/2023. (nms) (Entered: 04/11/2023)
4/5/2023
  • Motion to Dismiss (Demurrer)by Π
STIPULATION of Dismissal of Eli Lilly and Company and ICOS Corporation - by Eli Lilly and Company, Gilead Calistoga, LLC, Gilead Sciences, Inc., ICOS Corporation. (Tigan, Jeremy) (Entered: 04/05/2023)
2/23/2023
  • Motion to Extend Time
SO ORDERED, re 28 STIPULATION and Proposed Order to Extend Time for Certain Case Deadlines. Signed by Judge Richard G. Andrews on 2/23/2023. (nms) (Entered: 02/23/2023)
2/23/2023 STIPULATION and Proposed Order to Extend Time for Certain Case Deadlines - filed by Eli Lilly and Company, Gilead Calistoga, LLC, Gilead Sciences, Inc., ICOS Corporation. (Tigan, Jeremy) Modified on 2/23/2023 (nms). (Entered: 02/23/2023)
1/30/2023
  • Motion to Extend Time
SO ORDERED, re 27 STIPULATION and Proposed Order to Extend Time to (1) serve their initial infringement contention claim charts; and (2) to serve initial invalidity contentions and accompanying document production. Signed by Judge Richard G. Andrews on 1/30/2023. (nms) (Entered: 01/30/2023)
1/30/2023
  • Motion to Extend Timeby Π
STIPULATION TO EXTEND TIME for (1) Plaintiffs Gilead Sciences, Inc., Gilead Calistoga, LLC, Eli Lilly and Company, and ICOS Corporation to serve their initial infringement contention claim charts; and (2) Defendant Natco Pharma Limited to serve its initial invalidity contentions and accompanying document production to February 28, 2023 and March 30, 2023, respectively - filed by Eli Lilly and Company, Gilead Calistoga, LLC, Gilead Sciences, Inc., ICOS Corporation. (Tigan, Jeremy) (Entered: 01/30/2023)
1/13/2023
  • Motion to Extend Time
SO ORDERED, re 26 STIPULATION TO EXTEND TIME Defendants to serve Paragraph 3 Disclosures to January 17, 2023. Signed by Judge Richard G. Andrews on 1/13/2023. (nms) (Entered: 01/13/2023)
1/13/2023
  • Motion to Extend Timeby Δ
STIPULATION TO EXTEND TIME Defendants to serve Paragraph 3 Disclosures to January 17, 2023 - filed by Natco Pharma Limited. (Green, James) (Entered: 01/13/2023)
1/12/2023NOTICE OF SERVICE of Plaintiffs' Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Gilead Sciences, Inc., Eli Lilly and Company, Gilead Calistoga, LLC, ICOS Corporation.(Tigan, Jeremy) (Entered: 01/12/2023)
12/27/2022
  • Motion to Extend Time
SO ORDERED, re 24 STIPULATION to Extend Time to Serve Paragraph 3 Disclosures and Infringement and Invalidity Contentions to January 12, 2023, January 31, 2022 and March 2, 2023. Signed by Judge Richard G. Andrews on 12/27/2022. (nms) (Entered: 12/27/2022)
12/27/2022
  • Motion to Extend Timeby Δ
STIPULATION TO EXTEND TIME Time for Parties to Serve Paragraph 3 Disclosures and Infringement and Invalidity Contentions to January 12, 2023, January 31, 2022 and March 2, 2023 - filed by Natco Pharma Limited. (Green, James) (Entered: 12/27/2022)
11/8/2022NOTICE OF SERVICE of Defendant's Initial Disclosures Under Fed. R. Civ. P. 26(a)(1) filed by Natco Pharma Limited.(Green, James) (Entered: 11/08/2022)
11/7/2022NOTICE OF SERVICE of (1) Plaintiffs' Initial Rule 26 Disclosures and (2) Plaintiffs' Disclosures Pursuant to Paragraph 4(a) of the Delaware Default Standard for Discovery filed by Gilead Sciences, Inc., Eli Lilly and Company, Gilead Calistoga, LLC, ICOS Corporation.(Tigan, Jeremy) (Entered: 11/07/2022)
11/7/2022
  • OrderGranted
SO ORDERED Granting (D.I. 20 in 22-cv-852-RGA; D.I. 9 in 22-cv-1259-RGA) Proposed Stipulated Protective Order. Signed by Judge Richard G. Andrews on 11/7/2022. Associated Cases: 1:22-cv-00852-RGA, 1:22-cv-01259-RGA(nms) (Entered: 11/07/2022)
11/7/2022 PROPOSED Stipulated Protective Order, by Gilead Sciences, Inc., Eli Lilly and Company, Gilead Calistoga, LLC, ICOS Corporation. (Tigan, Jeremy) Modified on 11/7/2022 (nms). (Entered: 11/07/2022)
10/26/2022SO ORDERED, re 19 STIPULATION and Proposed Order Extending Time to File Protective Order to November 7, 2022. Signed by Judge Richard G. Andrews on 10/26/2022. (nms) (Entered: 10/26/2022)
10/26/2022 STIPULATION and Proposed Order Extending Time to file Protective Order to November 7, 2022 - filed by Natco Pharma Limited. (Green, James) Modified on 10/26/2022 (nms). (Entered: 10/26/2022)
9/28/2022
  • Motion to Appear Pro Hac Vice
SO ORDERED, re 18 MOTION for Pro Hac Vice Appearance of Attorney Charlotte C. Jacobsen, Christine Ranney, Darish Huynh and Kasturi Mitra, filed by Gilead Sciences, Inc., Gilead Calistoga, LLC. Signed by Judge Richard G. Andrews on 9/28/2022. (nms) (Entered: 09/28/2022)
9/28/2022
  • Motion to Appear Pro Hac Viceby Π
MOTION for Pro Hac Vice Appearance of Attorney Charlotte C. Jacobsen, Christine Ranney, Darish Huynh and Kasturi Mitra - filed by Gilead Calistoga, LLC, Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 09/28/2022)
9/27/202217
  • Order
ORAL ORDER: The Rule 16(b) Conference scheduled for 9/29/2022, is CANCELED. Ordered by Judge Richard G. Andrews on 9/27/2022. (nms) (Entered: 09/27/2022)
9/27/2022
  • Scheduling Order
SCHEDULING ORDER: Joinder of Parties due by 7/28/2023. Amended Pleadings due by 7/28/2023. Discovery due by 11/13/2023. Joint Claim Construction Brief due by 7/28/2023. A Markman Hearing is set for 8/29/2023, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 8/16/2024, at 9:00 AM in Courtroom 6A. A 3 day Bench Trial is set to start 8/26/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 9/27/2022. (nms) (Entered: 09/27/2022)
9/27/2022 PROPOSED Scheduling Order, by Eli Lilly and Company, Gilead Calistoga, LLC, Gilead Sciences, Inc., ICOS Corporation. (Tigan, Jeremy) Modified on 9/27/2022 (nms). (Entered: 09/27/2022)
9/8/2022
  • Order
Order Setting Rule 16(b) Telephone Conference: A Scheduling Conference is set for 9/29/2022, at 3:00 PM (see Order for further details). Signed by Judge Richard G. Andrews on 9/8/2022. (nms) (Entered: 09/08/2022)
9/6/2022 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Natco Pharma Limited. (Green, James) (Entered: 09/06/2022)
9/6/2022
  • Answer
ANSWER to 1 Complaint, and Affirmative Defenses, by Natco Pharma Limited.(Green, James) Modified on 9/6/2022 (nms). (Entered: 09/06/2022)
9/1/2022Pro Hac Vice Attorney Andrew O. Larsen, Christopher J. Sorenson, and Hayley M. Ostrin for Natco Pharma Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 09/01/2022)
8/30/2022
  • Motion to Appear Pro Hac Vice
SO ORDERED, re 11 MOTION for Pro Hac Vice Appearance of Attorney Christopher Sorenson, filed by Natco Pharma Limited, 10 MOTION for Pro Hac Vice Appearance of Attorney Hayley Ostrin, filed by Natco Pharma Limited, and 9 MOTION for Pro Hac Vice Appearance of Attorney Andrew Larsen, filed by Natco Pharma Limited. Signed by Judge Richard G. Andrews on 8/30/2022. (nms) (Entered: 08/30/2022)
8/30/2022
  • Motion to Appear Pro Hac Viceby Δ
MOTION for Pro Hac Vice Appearance of Attorney Christopher Sorenson - filed by Natco Pharma Limited. (Green, James) (Entered: 08/30/2022)
8/30/2022
  • Motion to Appear Pro Hac Viceby Δ
MOTION for Pro Hac Vice Appearance of Attorney Hayley Ostrin - filed by Natco Pharma Limited. (Green, James) (Entered: 08/30/2022)
8/30/2022
  • Motion to Appear Pro Hac Viceby Δ
MOTION for Pro Hac Vice Appearance of Attorney Andrew Larsen - filed by Natco Pharma Limited. (Green, James) (Entered: 08/30/2022)
8/29/2022
  • Motion to Extend Time
SO ORDERED re 8 STIPULATION and Proposed Order for Extension of Time to Respond to Complaint filed (*Reset Answer Deadlines: Natco Pharma Limited answer due 9/6/2022). Signed by Judge Richard G. Andrews on 8/29/2022. (nms) (Entered: 08/29/2022)
8/29/2022 STIPULATION and Proposed Order for Extension of Time to Respond to Complaint - filed by Natco Pharma Limited. (Green, James) Modified on 8/29/2022 (nms). (Entered: 08/29/2022)
7/12/2022WAIVER OF SERVICE returned executed by Gilead Sciences, Inc., Gilead Calistoga, LLC, Eli Lilly and Company, ICOS Corporation: For Natco Pharma Limited waiver sent on 6/29/2022, answer due 8/29/2022. (Tigan, Jeremy) (Entered: 07/12/2022)
6/29/2022Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 06/29/2022)
6/23/2022Summons Issued as to Natco Pharma Limited on 6/24/2022. (twk) (Entered: 06/24/2022)
6/23/2022 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Eli Lilly and Company for ICOS Corporation; Corporate Parent Gilead Sciences, Inc. for Gilead Calistoga, LLC filed by Eli Lilly and Company, Gilead Calistoga, LLC, Gilead Sciences, Inc., ICOS Corporation. (twk) (Entered: 06/24/2022)
6/23/2022Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE44,599 E; RE44,638 E; 8,865,730 B2; 9,469,643 B2; 10,730,879 B2. (twk) (Entered: 06/24/2022)
6/23/2022 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: May 11, 2022. Date of Expiration of RE44,599 Patent: July 21, 2025. Date of Expiration of RE44,638 Patent: August 5, 2025. Date of Expiration of 8,865,730 Patent: March 5, 2033. Date of Expiration of 9,469,643 Patent: September 2, 2033. Date of Expiration of 10,730,879 Patent: March 5, 2033. Thirty Month Stay Deadline: 11/11/2024. (twk) (Entered: 06/24/2022)
6/23/2022Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 06/24/2022)
6/23/2022
  • Complaint
COMPLAINT FOR PATENT INFRINGEMENT filed against Natco Pharma Limited ( Filing fee $ 402, receipt number ADEDC-3902222.) - filed by Gilead Sciences, Inc., Gilead Calistoga, LLC, Eli Lilly and Company, ICOS Corporation. (Attachments: # 1 Exhibit A-E, # 2 Civil Cover Sheet)(twk) (Entered: 06/24/2022)